• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.00% Nasdaq Down1.23%

    Advaxis, Inc. (ADXS)

    -NasdaqCM
    7.49 Down 0.31(3.97%) 10:04AM EDT - Nasdaq Real Time Price
    ProfileGet Profile for:
    Advaxis, Inc.
    305 College Road East
    Princeton, NJ 08540
    United States - Map
    Phone: 609-452-9813
    Fax: 609-452-9818
    Website: http://www.advaxis.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:48

    Business Summary 

    Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac (ADXS-HPV), an Lm-LLO immunotherapy product candidate, which completed its Phase II study used for the treatment of human papilloma virus (HPV) associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen (PSA) antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has clinical trial collaboration agreements with Merck & Co., Inc. for the Phase I/II dose-escalation and safety study of ADXS31-142; MedImmune, LLC to initiate a Phase I/II clinical study in the United States to evaluate the safety and efficacy of MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV; and Incyte Corporation for the development and analysis of a combination therapy for the treatment of cervical cancer. The company also has a licensing agreement with Global BioPharma, Inc.; and development and commercialization agreement with Especificos Stendhal SA de CV. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Advaxis, Inc.

    Corporate Governance 
    Advaxis, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 3; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Daniel J. O'Connor Esq., 51
    Chief Exec. Officer, Pres and Director
    546.00K0.00
    Mr. Gregory T. Mayes Esq., 47
    Chief Operating Officer, Exec. VP and Director
    440.00K0.00
    Ms. Sara M. Bonstein MBA, 35
    Chief Financial Officer and Sr. VP
    N/AN/A
    Dr. Robert G. Petit Ph.D., 56
    Chief Scientific Officer and Exec. VP
    N/AN/A
    Mr. Mayo Pujols ,
    VP of Manufacturing
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders